3
Announcements
Trials
Browse
Landscape
Status
Recruiting
1
Completed
1
Sponsor Class
OTHER
1
Study Type
Observational
1
Sponsor
Cancer Type
Other hematologic neoplasm
1
Lymphoid
1
Conditions
Prostatic Neoplasms
26
Lymphoma, Large B-Cell, Diffuse
19
Burkitt Lymphoma
13
Precursor Cell Lymphoblastic Leukemia-Lymphoma
9
Lymphoma, T-Cell, Peripheral
8
Lymphoma, Follicular
8
Lymphoma, B-Cell
7
Lymphoma
7
Neoplasms
5
Lymphoma, Non-Hodgkin
5
Precursor T-Cell Lymphoblastic Leukemia-Lymphoma
3
Neoplasm Metastasis
3
Leukemia, Biphenotypic, Acute
3
Recurrence
2
Prostatic Neoplasms, Castration-Resistant
2
Precursor B-Cell Lymphoblastic Leukemia-Lymphoma
2
Plasmablastic Lymphoma
2
Ovarian Neoplasms
2
Myasthenia Gravis
2
Lymphoma, Mantle-Cell
2
Lymphoma, B-Cell, Marginal Zone
2
Leukemia, Lymphocytic, Chronic, B-Cell
2
Endometrial Neoplasms
2
Carcinoma, Non-Small-Cell Lung
2
Urogenital Neoplasms
1
Triple Negative Breast Neoplasms
1
Stomach Neoplasms
1
Prostatic Diseases
1
Prostate Cancer Metastatic
1
Prostate Adenocarcinoma
1
Interventions
Cyclophosphamide
7
venetoclax
6
Azacitidine
6
fludarabine
5
Cytarabine
4
Blood Specimen Collection
4
daratumumab
3
Lenalidomide
3
Daunorubicin
3
tislelizumab
2
fludarabine phosphate
2
blinatumomab
2
Rituximab
2
Liquid Biopsy
2
Idarubicin
2
Gemtuzumab
2
Capecitabine
2
Busulfan
2
trastuzumab deruxtecan
1
thymoglobulin
1
tetrathiomolybdate
1
talquetamab
1
tagraxofusp
1
sugemalimab
1
sacituzumab govitecan
1
relugolix
1
pembrolizumab
1
pegaspargase
1
palbociclib
1
obinutuzumab
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Recruiting
×
Neoplasm, Residual
×
Prednisone
×
Clear all
NCT05959720
2025-05-07
BRALLA
Instituto do Cancer do Estado de São Paulo
Recruiting
180 enrolled